Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose

dc.creatorRossi, Andrés Hugo
dc.creatorOjeda, Diego Sebastian
dc.creatorVarese, Augusto
dc.creatorSanchez, Lautaro Nicolas
dc.creatorGonzález López Ledesma, María Mora
dc.creatorMazzitelli, Ignacio Gabriel
dc.creatorAlvarez Juliá, Anabel
dc.creatorOviedo Rouco, Santiago
dc.creatorPallarés, Horacio Martín
dc.creatorCosta Navarro, Guadalupe Soledad
dc.creatorRasetto, Natalí Belén
dc.creatorGarcia, Corina Ileana
dc.creatorWenker, Shirley Denise
dc.creatorRamis, Lila Yanina
dc.creatorBialer, Magali Graciela
dc.creatorde Leone, María José
dc.creatorHernando, Carlos Esteban
dc.creatorSosa, Santiago
dc.creatorBianchimano, Luciana
dc.creatorRios, Antonella Soledad
dc.creatorTreffinger Cienfuegos, Maria Soledad
dc.creatorCaramelo, Julio Javier
dc.creatorLongueira, Yesica Soledad
dc.creatorLaufer, Natalia Lorna
dc.creatorAlvarez, Diego Ezequiel
dc.creatorCarradori, Jorge
dc.creatorPedrozza, Dariana
dc.creatorRima, Alejandra
dc.creatorEchegoyen, Cecilia
dc.creatorErcole, Regina
dc.creatorGelpi, Paula
dc.creatorMarchetti, Susana
dc.creatorZubieta, Martín
dc.creatorDocena, Guillermo H.
dc.creatorKreplak, Nicolas
dc.creatorYanovsky, Marcelo Javier
dc.creatorGeffner, Jorge Raúl
dc.creatorPifano, Marina
dc.creatorGamarnik, Andrea Vanesa
dc.date.accessioned2021-09-17T15:17:03Z
dc.date.accessioned2022-10-15T16:45:32Z
dc.date.available2021-09-17T15:17:03Z
dc.date.available2022-10-15T16:45:32Z
dc.date.created2021-09-17T15:17:03Z
dc.date.issued2021-08
dc.identifierRossi, Andrés Hugo; Ojeda, Diego Sebastian; Varese, Augusto; Sanchez, Lautaro Nicolas; González López Ledesma, María Mora; et al.; Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose; Cell Press; Cell Reports Medicine; 2; 8; 8-2021; 1-16
dc.identifier2666-3791
dc.identifierhttp://hdl.handle.net/11336/140691
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4411045
dc.description.abstractMassive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.
dc.languageeng
dc.publisherCell Press
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2666379121002081
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.xcrm.2021.100359
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectCOVIDAR IGG
dc.subjectNEUTRALIZING ANTIBODIES
dc.subjectSARS-COV-2 VACCINATION
dc.subjectSEROCONVERSION
dc.subjectSPUTNIK V
dc.subjectWHO SARS-COV-2 ANTIBODY INTERNATIONAL STANDARD
dc.titleSputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución